Chromosomal and Genomic Changes in Lung Cancer

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2010 Feb 9

PMID 20139701

Citations 25

Authors

Marileila Varella-Garcia

Affiliations

Soon will be listed here.

Abstract

Lung cancer is a complex spectrum of diseases characterized by extensive genomic instability, which can be detected among both histological subtypes and different foci within a tumor. Conventional and cutting edge investigative technologies have uncovered scores of genomic changes in individual specimens that have been used to characterize specific molecular subtypes. Oncogenes with predominant roles in lung cancer include EGFR, MYC and RAS family members, PIK3CA, NKX2-1 and ALK; tumor suppressor genes include TP53, RB1, CDKN2, and a cluster of genes mapped at 3p. MicroRNA regulators also have been linked to lung cancer. The functional role of the recurrent genomic changes in lung tumors has been explored, which has led to a better understanding of cell growth, differentiation and apoptotic pathways. Additionally, this knowledge has supported the development of novel therapeutics and translational tools for selection of patients for personalized therapy.

Citing Articles

Defining the landscape of circRNAs in non-small cell lung cancer and their potential as liquid biopsy biomarkers: a complete review including current methods.

Pedraz-Valdunciel C, Rosell R Extracell Vesicles Circ Nucl Acids. 2024; 2(2):179-201.

PMID: 39697533 PMC: 11648509. DOI: 10.20517/evcna.2020.07.

A genomic instability-associated lncRNA signature for predicting prognosis and biomarkers in lung adenocarcinoma.

Lin C, Lin K, Li P, Yuan H, Lin X, Dai Y Sci Rep. 2024; 14(1):14460.

PMID: 38914679 PMC: 11196711. DOI: 10.1038/s41598-024-65327-3.

Lung cancer clustering by identification of similarities and discrepancies of DNA copy numbers using maximal information coefficient.

N Kachouie N, Deebani W, Shutaywi M, Christiani D PLoS One. 2024; 19(5):e0301131.

PMID: 38739669 PMC: 11090345. DOI: 10.1371/journal.pone.0301131.

Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer.

Forder A, Zhuang R, Souza V, Brockley L, Pewarchuk M, Telkar N Int J Mol Sci. 2023; 24(3).

PMID: 36769181 PMC: 9918127. DOI: 10.3390/ijms24032859.

The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

He J, Wang Z, Wang Y, Zou T, Li X, Chen J Dis Markers. 2022; 2022:3306189.

PMID: 36277983 PMC: 9584701. DOI: 10.1155/2022/3306189.

References

Toyooka S, Tsuda T, Gazdar A . The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003; 21(3):229-39. DOI: 10.1002/humu.10177. View

Lockwood W, Chari R, Coe B, Girard L, MacAulay C, Lam S . DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008; 27(33):4615-24. PMC: 2849646. DOI: 10.1038/onc.2008.98. View

Zhu C, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N . Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26(26):4268-75. DOI: 10.1200/JCO.2007.14.8924. View

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

Marks J, Broderick S, Zhou Q, Chitale D, Li A, Zakowski M . Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3(2):111-6. DOI: 10.1097/JTO.0b013e318160c607. View

Kimura S, Hara Y, Pineau T, Fox C, Ward J, Gonzalez F . The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996; 10(1):60-9. DOI: 10.1101/gad.10.1.60. View

Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen K, Lakshmi B . Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A. 2007; 104(42):16663-8. PMC: 2034240. DOI: 10.1073/pnas.0708286104. View

Weir B, Woo M, Getz G, Perner S, Ding L, Beroukhim R . Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450(7171):893-8. PMC: 2538683. DOI: 10.1038/nature06358. View

Singhal S, Vachani A, Antin-Ozerkis D, Kaiser L, Albelda S . Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005; 11(11):3974-86. DOI: 10.1158/1078-0432.CCR-04-2661. View

10.

Lai W, Chen F, Wu M, Chow N, Su W, Ma M . Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg. 2002; 72(6):1868-76. DOI: 10.1016/s0003-4975(01)03207-6. View

11.

Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, Houdayer C . Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics. 2008; 1:25. PMC: 2527324. DOI: 10.1186/1755-8794-1-25. View

12.

Schrock E, Du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith M . Multicolor spectral karyotyping of human chromosomes. Science. 1996; 273(5274):494-7. DOI: 10.1126/science.273.5274.494. View

13.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

14.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

15.

Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T . Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 1997; 20(4):399-407. View

16.

Massarelli E, Varella-Garcia M, Tang X, Xavier A, Ozburn N, Liu D . KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007; 13(10):2890-6. DOI: 10.1158/1078-0432.CCR-06-3043. View

17.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

18.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

19.

Speicher M, Gwyn Ballard S, Ward D . Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet. 1996; 12(4):368-75. DOI: 10.1038/ng0496-368. View

20.

Subramanian J, Govindan R . Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25(5):561-70. DOI: 10.1200/JCO.2006.06.8015. View